Reference Detail

Ref Type

PMID

Authors

Ilana Mandel, Dana Haves, Ilana Goldshtein, Tsuri Peretz, Dror Alishekevitz, Yair Sapir, Sharon Hashmueli, Itay Friedman and Tehila Ben Moshe

Title

Abstract 3266: BND-22, a first-in-class, anti-ILT2 monoclonal antibody inhibits the immunosuppressive effects of HLA-G and enhances anti-tumor activity of immune cells in preclinical in vitro, ex vivo, and in vivo models

Journal	Vol	Issue	Date	Pages	Journal Short Title
Cancer Research	80	16	2020

URL

https://cancerres.aacrjournals.org/content/80/16_Supplement/3266

Abstract Text

Background: Ig-like transcripts (ILTs) are a family of immuno-modulating receptors expressed on immune cells. ILT2 is an inhibitory receptor expressed on both innate and adaptive immune cells. It has been shown to bind to MHC class I molecules and binds with the highest affinity to HLA-G, an immunosuppressive MHC molecule expressed by multiple tumor types. ILT2-mediated inhibition can lead to impairment of immune cell proliferation, differentiation, phagocytosis, cytotoxicity and cytokine secretion, identifying the ILT2 signaling axis as a potential novel target for anti-cancer immunotherapy. Here we describe preclinical characterization of BND-22, a humanized IgG4, ILT2 antagonist antibody developed for the treatment of solid tumors. Methods: BND-22 binding to ILT2 was evaluated by flow cytometry, ELISA and surface plasmon resonance. We investigated the ability of BND-22 to reverse ILT2-mediated immune suppression of macrophages and lymphocytes. Macrophage and NK cell effector functions were studied in vitro and ex vivo in the presence of several cancer cell lines and patient tumor tissues using flow cytometry, time-lapse live-cell-microscopy, and functional cell-based assays. Xenograft subcutaneous melanoma and colorectal carcinoma and melanoma lung metastases models were used to evaluate the in vivo anti-tumor effect of BND-22. Results: BND-22 binds ILT2, but not other ILT-family receptors, with low nanomolar affinity and blocks its interaction with HLA-G in a concentration-dependent manner. ILT2 blockade with BND-22 increased macrophage-mediated phagocytosis of tumor cell lines and patient-excised tumors, enhanced the cytotoxicity of NK cells against multiple types of cancer cells, and increased NK cell production of Granzyme B and IFNγ. ILT2 and PD-1 were found to be expressed by different sub-populations of CD45+ cells. Co-blockade of ILT2 and PD-1 showed a synergistic effect in increasing pro-inflammatory cytokine production by patient-derived PBMC in response to autologous tumor cells. In subcutaneous melanoma and colorectal carcinoma xenograft mouse models, BND-22 enhanced the anti-tumor activity of macrophages, inhibited tumor growth and prolonged survival. BND-22 also potently increased the anti-tumor activity of lymphocytes and inhibited metastases spread in an in vivo melanoma lung lesion model. Conclusions: BND-22, a first-in-class, anti-ILT2 antagonist antibody induces a potent macrophage and lymphocyte-driven anti-tumor immune response in multiple in vitro, ex vivo and in vivo models. BND-22 offers a differentiated, multi immune cell-based mechanism of action. Safety, tolerability, and anti-tumor activity of BND-22 will be explored in a first-in-human clinical trial in cancer patients with tumor types known to express HLA-G.

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials
BND-22	BND-22	0	1

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
BND-22		BND22\|BND 22		BND-22 is an anti-ILT2 monoclonal antibody that blocks ILT2 from interacting with HLA-G, potentially leading to immunosuppressive effects and subsequent anti-tumor activity, including increased macrophage activity and inhibition of tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 3266).

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References